Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astellas Pharma ADR Representing 1 Ord Shs ALPMY

Healthcare
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.

Recent & Breaking News (PINL:ALPMY)

Astellas Pharma Launches the Newest Element in its Global Corporate Brand Campaign On CNN's Global Broadcast Network

PR Newswire February 13, 2015

Astellas Broadens Commitment to Clinical Trial Data Transparency

PR Newswire February 2, 2015

Astellas Pharma Inc. Hires Global Executive Eric Terhaerdt to Lead Global Development Operations

PR Newswire January 15, 2015

Dana-Farber Cancer Institute And Astellas Announce Research Collaboration

PR Newswire November 4, 2014

Astellas Announces Research Collaboration With Harvard Medical School Investigator For Treatment Of Retinal Degeneration

PR Newswire October 14, 2014

U.S. FDA Approves New Indication for the Use of XTANDI® (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer

PR Newswire September 10, 2014

Astellas Details Pipeline Progress at R&D Meeting

PR Newswire July 11, 2014

Astellas and Medivation Receive Priority Review from FDA for XTANDI® (Enzalutamide) Capsules In Chemotherapy-Naive Advanced Prostate Cancer

PR Newswire May 6, 2014

Astellas Pharma US, Inc. reaches agreement with U.S. Department of Justice

PR Newswire April 16, 2014

Astellas US Promotes Jeffrey Bloss to SVP of Medical Affairs for the Americas

PR Newswire April 16, 2014

Astellas Announces European Regulatory Submission For XTANDI® (enzalutamide) Capsules For Chemotherapy-Naive Metastatic Prostate Cancer

PR Newswire April 3, 2014

Astellas Announces Marketing Authorisation Application for XTANDI(TM) (enzalutamide) for Chemotherapy-Naïve Metastatic Prostate Cancer

PR Newswire April 3, 2014

Astellas Announces Marketing Approval in Japan for XTANDI® (enzalutamide) Capsules, an Advanced Prostate Cancer Treatment

PR Newswire March 24, 2014

Astellas Pharma and Daiichi Sankyo Form Compound Library Sharing Partnership

PR Newswire March 19, 2014

Astellas Secures Exclusive Rights to Commercialize Isavuconazole in the U.S. and Canada

PR Newswire February 28, 2014

FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Mucormycosis

PR Newswire February 27, 2014

Astellas and Vical Announce Initiation of Phase 2 Trial of ASP0113, a Cytomegalovirus Vaccine, in Solid Organ Transplant Recipients

PR Newswire December 10, 2013

Astellas reports positive topline phase 3 results for antifungal isavuconazole

PR Newswire September 30, 2013

New Survey Reveals U.S. Men with Advanced Prostate Cancer Worry More about Burdening Family and Friends Than Dying

PR Newswire September 26, 2013

Astellas to Host Executive Women's Day at 2013 TOUR Championship by Coca-Cola

PR Newswire September 17, 2013